Turning off the BCL-2 switch to prevent intestinal tumorigenesis.
Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center, Amsterdam, The Netherlands.
Maartje
M
van der Heijden
Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Douglas J
DJ
Winton
Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center, Amsterdam, The Netherlands.
Louis
L
Vermeulen
D000236:Adenoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D051379:Mice; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000172:deficiency* / Q000378:metabolism
D019253:Proto-Oncogene Proteins c-bcl-2
Bcl-2; apoptosis; chemoprevention; colorectal carcinoma; intestinal stem cells